Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30880341 | 0.95 | NAAA (0.45) | QPCTSMN1; SMN2MAPK1HTTNAAA | |
| SCHEMBL7557165 | 0.94 | NAAA (0.48) | SMN1; SMN2MAPK1HTTNAAAEPHX1 | |
| SCHEMBL2851679 | 0.94 | NAAA (0.48) | SMN1; SMN2MAPK1HTTNAAAEPHX1 | |
| SCHEMBL10057549 | 0.94 | NAAA (0.48) | SMN1; SMN2MAPK1HTTNAAAEPHX1 | |
| SCHEMBL5257422 | 0.90 | QPCT (0.45) | QPCTSMN1; SMN2MAPK1LMNAL3MBTL1 | |
| SCHEMBL15212788 | 0.88 | TSHR (0.39) | QPCTSMN1; SMN2MAPK1LMNAHTT | |
| SCHEMBL7553681 | 0.86 | EPHX2 (0.47) | — | |
| SCHEMBL22494115 | 0.86 | EPHX2 (0.47) | — | |
| SCHEMBL7553680 | 0.86 | EPHX2 (0.47) | — | |
| SCHEMBL4375579 | 0.85 | KMT2A (0.38) | QPCTSMN1; SMN2MAPK1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3157523-B1 | MULTIFUNCTIONAL AMINOQUINOLINE THERAPEUTIC AGENTS | LOHOCLA RES CORPORATION (US) | 2025-03-19 | — | — | EP | disclosed |
| US-11130737-B2 | Multifunctional aminoquinoline therapeutic agents | LOHOCLA RESEARCH CORPORATION (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200095204-A1 | MULTIFUNCTIONAL AMINOQUINOLINE THERAPEUTIC AGENTS | LOHOCLA RESEARCH CORPORATION | 2020-03-26 | — | — | US | disclosed |
| US-10435371-B2 | Multifunctional aminoquinoline therapeutic agent | LOHOCLA RESEARCH CORPORATION (US) | 2019-10-08 | — | — | US | disclosed |
| US-10391088-B2 | Analgesic compositions | LOHOCLA RESEARCH CORPORATION (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190099412-A1 | ANALGESIC COMPOSITIONS | LOHOCLA RESEARCH CORPORATION | 2019-04-04 | — | — | US | disclosed |
| US-20190092731-A1 | MULTIFUNCAIONAL AMINOQUINOLINE THERAPEUTIC AGENT | LOHOCLA RESEARCH CORPORATION | 2019-03-28 | — | — | US | disclosed |
| US-10112905-B2 | Multifunctional aminoquinoline therapeutic agents | LOHOCLA RESEARCH CORPORATION (US) | 2018-10-30 | — | — | US | disclosed |
| US-20170204064-A1 | MULTIFUNCTIONAL AMINOQUINOLINE THERAPEUTIC AGENTS | LOHOCLA RESEARCH CORPORATION | 2017-07-20 | — | — | US | disclosed |
| US-20170204064-A1 | MULTIFUNCTIONAL AMINOQUINOLINE THERAPEUTIC AGENTS | LOHOCLA RESEARCH CORPORATION | 2017-07-20 | — | — | US | disclosed |
| US-9556314-B2 | Polyphosphazenes | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2017-01-31 | — | — | US | disclosed |
| US-9556314-B2 | Polyphosphazenes | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2017-01-31 | — | — | US | disclosed |
| WO-2015195943-A1 | MULTIFUNCTIONAL AMINOQUINOLINE THERAPEUTIC AGENTS | LOHOCLA RESEARCH CORPORATION (US) | 2015-12-23 | — | — | WO | disclosed |
| US-20150141540-A1 | POLYPHOSPHAZENES | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2015-05-21 | — | — | US | disclosed |
| US-8168647-B2 | Vinblastine derivatives, their preparation, use and pharmaceutical compositions comprising the said derivatives | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2012-05-01 | — | — | US | disclosed |
| US-8168647-B2 | Vinblastine derivatives, their preparation, use and pharmaceutical compositions comprising the said derivatives | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2012-05-01 | — | — | US | disclosed |
| US-20100113498-A1 | NOVEL VINBLASTINE DERIVATIVES, THEIR PREPARATION, USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAID DERIVATIVES | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2010-05-06 | — | — | US | disclosed |
| US-20100113498-A1 | NOVEL VINBLASTINE DERIVATIVES, THEIR PREPARATION, USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAID DERIVATIVES | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2010-05-06 | — | — | US | disclosed |
| EP-2119720-A1 | NOVEL VINBLASTINE DERIVATIVES, THEIR PREPARATION, USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAID DERIVATIVES | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2009-11-18 | — | — | EP | disclosed |
| WO-2009046098-A1 | NOVEL CYCLIC BORONATE INHIBITORS OF HCV REPLICATION | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130737-B2 | Multifunctional aminoquinoline therapeutic agents | OPRK1, OPRM1, OPRD1 | QPCT 77/4885SMN1; SMN2 925/4885MAPK1 2310/4885 |
| US-20200095204-A1 | MULTIFUNCTIONAL AMINOQUINOLINE THERAPEUTIC AGENTS | OPRK1, OPRM1, OPRD1 | QPCT 77/4885SMN1; SMN2 925/4885MAPK1 2310/4885 |
| US-10391088-B2 | Analgesic compositions | OPRK1, OPRL1, OPRM1 | QPCT 953/4885SMN1; SMN2 1119/4885MAPK1 3124/4885 |
| US-20190099412-A1 | ANALGESIC COMPOSITIONS | OPRK1, OPRL1, OPRM1 | QPCT 953/4885SMN1; SMN2 1119/4885MAPK1 3124/4885 |
| US-20100113498-A1 | NOVEL VINBLASTINE DERIVATIVES, THEIR PREPARATION, USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAID DERIVATIVES | MCL1, BAX, BAD | QPCT 2593/4885SMN1; SMN2 1154/4885MAPK1 1250/4885 |
| US-20190092731-A1 | MULTIFUNCAIONAL AMINOQUINOLINE THERAPEUTIC AGENT | OPRK1, OPRL1, PNMT | QPCT 33/4885SMN1; SMN2 1112/4885MAPK1 2460/4885 |
| US-20170204064-A1 | MULTIFUNCTIONAL AMINOQUINOLINE THERAPEUTIC AGENTS | OPRK1, OPRM1, OPRD1 | QPCT 97/4885SMN1; SMN2 850/4885MAPK1 2290/4885 |
| US-10435371-B2 | Multifunctional aminoquinoline therapeutic agent | OPRK1, OPRM1, OPRD1 | QPCT 88/4885SMN1; SMN2 793/4885MAPK1 2551/4885 |
| US-10112905-B2 | Multifunctional aminoquinoline therapeutic agents | OPRK1, OPRM1, OPRD1 | QPCT 97/4885SMN1; SMN2 850/4885MAPK1 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.